Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

No More Sarepta-Like Development, FDA Officials Say

Related Content

Patient Advocacy With FDA Review Staff Will Be Tougher Post-Sarepta

Sep 23 2016

Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry

Sep 21 2016

Political Appointees Shouldn't Influence Approval Decisions, Califf Says

Oct 20 2016

Accelerated Approval Should Be Less 'Wide Open,' Califf Says

Oct 20 2016

Duchenne Group's Presentation Is Milestone For Patient Involvement

May 02 2016

Duchenne Muscular Dystrophy: Second Product Isn't The Charm

Jan 15 2016

Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template

Oct 15 2016

Sarepta Must Balance Exondys 51 Confirmatory Trials And Sales

Sep 23 2016

Related Companies

Sarepta Therapeutics, Inc.

PTC Therapeutics, Inc.

BioMarin Pharmaceutical Inc.

Additional Topics

United States Approvals Clinical Trials Drug Approval Standards Drug Review Regulation BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window